Article
Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Molecular and cellular endocrinology - 15 Aug 2018
Stires Hillary, Heckler Mary M, Fu Xiaoyong, Li Zhao, Grasso Catherine S, Quist Michael J, Lewis Joseph A, Klimach Uwe, Zwart Alan, Mahajan Akanksha, Győrffy Balázs, Cavalli Luciane R, Riggins Rebecca B
Abstract excerpt
Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha positive (ER+) ILC has a poor response to Tamoxifen (TAM), but the mechanistic drivers of this are undefined. In the current work, we comprehensively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.